Figure 2-4. Evolution de la prévalence globale standardisée de l'insuffisance rénale terminale traitée par dialyse ou greffe entre 2012 et 2017 (taux standardisés sur la population française au 31/12/2017 par million d'habitants)

**Prévalence 2019**

55000 dialysés

45000 transplantés

**Entre 3 et 4**

**millions**

**de**

**MRC stades 3-4**

Diabète = 1<sup>re</sup> cause d'IRC en France

Figure 1-8. Tendance de l'incidence de l'insuffisance rénale terminale associée ou non au diabète
(taux standardisés sur la population française au 30/06/2017, par million d'habitants)

Société Francophone de Néphrologie, Dialyse et Transplantation

Réseau
Epidémiologie,
Information,
Néphrologie

Registre français des traitements de suppléance
de l'insuffisance rénale chronique

Prediction of CKD 3, 4 & 5 prevalence in diabetic patients

Kainz A. NDT 2015

Société Francophone de Néphrologie, Dialyse et Transplantation

Réseau
Epidémiologie,
Information,
Néphrologie

Registre français des traitements de suppléance
de l'insuffisance rénale chronique

Figure 1-12. Evolution du nombre de malades incidents non diabétiques
en insuffisance rénale terminale traitée
Trends in number of non diabetic treated ESRD patients



Figure 1-11. Evolution du nombre de malades incidents diabétiques en insuffisance rénale terminale
traitée
Trends in number of treated ESRD patients associated with diabetes

# Stratification du risque, adressage, traitement

| | | | | Albuminuria categories Description and range | | |
|---|---|---|---|---|---|---|
| | | | | **A1** | **A2** | **A3** |
| CKD is classified based on: • Cause (C) • GFR (G) • Albuminuria (A) | | | | Normal to mildly increased | Moderately increased | Severely increased |
| | | | | <30 mg/g <3 mg/mmol | 30–299 mg/g 3–29 mg/mmol | ≥300 mg/g ≥30 mg/mmol |
| GFR categories (mL/min/1.73 m²) Description and range | **G1** | Normal or high | ≥90 | Screen 1 | Treat 1 | Treat and refer 3 |
| | **G2** | Mildly decreased | 60–89 | Screen 1 | Treat 1 | Treat and refer 3 |
| | **G3a** | Mildly to moderately decreased | 45–59 | Treat 1 | Treat 2 | Treat and refer 3 |
| | **G3b** | Moderately to severely decreased | 30–44 | Treat 2 | Treat and refer 3 | Treat and refer 3 |
| | **G4** | Severely decreased | 15–29 | Treat and refer* 3 | Treat and refer* 3 | Treat and refer 4+ |
| | **G5** | Kidney failure | <15 | Treat and refer 4+ | Treat and refer 4+ | Treat and refer 4+ |

Low risk (if no other markers of kidney disease, no CKD)　　High risk

Moderately increased risk　　Very high risk